Novartis Gets Immune-Cell Cancer Therapy in UPenn Pact

Novartis AG will fund a $20 million research center at the University of Pennsylvania in a deal in which the drugmaker gains technology that uses manipulated immune-system cells to fight cancer.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.